title: No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
abstract: OBJECTIVE
  To investigate whether there is an association of antipsychotic agent-induced weight gain with the TaqI A polymorphism of dopamine D2 receptor (DRD2) gene and therapeutic response to antipsychotic treatment in schizophrenia.
  
  
  METHODS
  Genotyping was performed using the PCR-RFLP techniques in a total of 117 first-episode Chinese Han schizophrenic patients (mean age 26+/-8 a; 58 male, 59 female). Moreover, the measurements were finished either for baseline weight and body mass index (BMI) or for changed weight and BMI 10 weeks after antipsychotic treatment. The Positive and Negative Symptom Scale (PANSS) was used for the evaluation of the improvement of clinical psychotic symptoms.
  
  
  RESULTS
  There was an average increase in body weight of (3+/-3) kg or (6+/-6) % of baseline weight with a changed range of -7 kg - 12 kg or -7.8 % - 32.4 % 10 weeks after treatment, and the change in the BMI was associated with the baseline BMI and patients' age (P=0.0001; P=0.03; respectively). However, there was no significant difference in distribution of allelic frequencies (X2=0.65, v1, P>0.05) and genotype (x2=1.47, v2, P>0.05) between the subgroups, and the change in BMI was not associated with genotypes of DRD2. Furthermore, there was no relationship of the therapeutic response to antipsychotic treatment with changed BMI in the patients (P>0.05).
  
  
  CONCLUSIONS
  The TaqI A polymorphism of DRD2 gene is therefore unlikely to play an important role in antipsychotic agent-induced weight gain, a side effect of antipsychotic treatment. Furthermore, increase in body weight is unlikely to be prediction of therapeutic response to antipsychotic treatment in schizophrenia.
authors.affiliation: Department of Psychiatry, Nanjing Brain Hospital, Nanjing Medical University, 210029, China. LbiCheng@public1.ptt.js.cn
authors.forename: Zhi-Jun
authors.initials: ZJ
authors.lastname: Zhang
authors.forename: Zhi-Jian
authors.initials: ZJ
authors.lastname: Yao
authors.forename: Xiao-Bin
authors.initials: XB
authors.lastname: Zhang
authors.forename: Jian-Fang
authors.initials: JF
authors.lastname: Chen
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Hui
authors.initials: H
authors.lastname: Yao
authors.forename: Gang
authors.initials: G
authors.lastname: Hou
authors.forename: Xin-Bao
authors.initials: XB
authors.lastname: Zhang
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D015992:Body Mass Index; D002746:Chlorpromazine / Q000009:adverse effects; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D008297:Male; D012150:Polymorphism, Restriction Fragment Length; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D002746:Chlorpromazine